Navigation Links
Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
Date:3/24/2008

p>2007 Financial Results

Ardea's 2007 year-end cash balance was $66.2 million, compared to $48.7 million for the 2006 year-end cash balance. The December 31, 2007 cash balance includes net proceeds of $37.2 million from a private placement of common stock in December 2007.

The net loss for the fourth quarter 2007 was $9.1 million, or $0.86 per share, compared to a net loss for the same period in 2006 of $0.5 million, or $0.05 per share. The net loss for the year ended December 31, 2007 was $25.3 million, or $2.55 per share, compared to a net loss for the year ended December 31, 2006 of $0.6 million, or $0.07 per share. The net loss for the quarter and full-year ended December 31, 2007 included non-cash stock-based compensation expense of $0.6 million, or $0.05 per share, and $1.4 million, or $0.14 per share, respectively. The difference between the Company's 2007 and 2006 results reflects the rebuilding of its operations combined with the advancement and expansion of its preclinical and clinical drug development programs.

Revenues for the fourth quarter of 2007 were $0.3 million, compared to zero for the same period in 2006. Revenues for the full-year 2007 were $3.1 million compared to zero for 2006. The increase is due to research performed by the Company as part of a master services agreement with Valeant.

2008 Financial Guidance

On December 31, 2007, the Company had a total of $66.2 million in cash, cash equivalents and short-term investments. Excluding any funds that Ardea may receive from future business development activities, the Company anticipates 2008 net cash usage to be between $45 million and $50 million.

About Ardea Biosciences

Ardea Biosciences, of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have three drug candidates in clinical trials and several
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
2. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
3. Pressure BioSciences, Inc. Announces Move to New Corporate Offices
4. Numira Biosciences Names New Board Member
5. DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
6. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
7. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
8. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
9. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... A common approach to treating kidney failure ... improve survival chances for people who suddenly developed the ... University of Pittsburgh School of Medicine. ... PLOS One , suggest acute hemodialysis, an aggressive ... kidney failure, may not provide a definitive benefit to ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Quincy Bioscience, ... Inc. 500|5000 list of the fastest growing private ... year. Ranking at No. 2,941, Quincy Bioscience is honored ... in the United States. , Quincy Bioscience is manufacturer ... apoaequorin – a protein originally discovered in jellyfish and ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The non-small ... increase considerably in the offing across the top 8 ... of 2013 to around USD 8 billion by 2020-end, ... The growth is projected to be driven by innovative ... is currently lacking efficient treatment, unlike the non-squamous segment. ...
(Date:8/20/2014)... By Steven Reinberg ... -- A rare birth disorder that dismantles a baby,s immune ... study of more than 3 million infants says. This ... for the life-threatening but treatable condition known as severe combined ... "People were made aware of this condition by the boy ...
(Date:8/20/2014)... -- New research reveals that, long ago, sea mammals ... of the infectious disease known as tuberculosis. Ancient ... seals and sea lions, who then spread it to ... to an international team of researchers. "Tuberculosis is ... This study and further research will help us understand ...
Breaking Medicine News(10 mins):Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:Quincy Bioscience Recognized in Inc. 500|5000 List of America’s Fastest Growing Companies for Third Consecutive Year 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Seals, Sea Lions Helped Global Spread of TB, Study Finds 2
... , MASON, Ohio, Aug. 10 ... physicians representing the Women,s Dermatologic Society (WDS) will provide ... enjoying the Western & Southern Financial Group Master,s and Women,s ... a.m.-5:00 p.m. Led by board-certified dermatologist Allison Moosally, MD (Cleveland), ...
... PHILADELPHIA, August 10 , ... of System,s,Nine-Year "Journey to Excellence"; Elsevier Becomes Primary Information,Source ... http://www.elsevier.com ), a world leader in healthcare and,medical publishing ... of the top 10 Catholic health systems in the ...
... August 10 , - ... Help,Prevent Costly Mistakes; Hospitals Benefit From Averting the Reimbursement,Losses ... in healthcare and medical publishing and online,solutions, today announced ... Consult designed to help nurses prevent the 10 "Never ...
... ... US Drug Watchdog is intensifying its national efforts to get the word out ... Remedy Swabs. According to the group, "Our reasons are pretty simple. We fear ... has said, use of the products could result in a loss of taste, ...
... ... ... Tucson, Arizona is home to a dense Hispanic population. In recognition of September 15th ... word throughout the local Hispanic community that colorectal pre-screening can save lives., , , ...
... ... the publicly available iHOP database enables researchers to quickly and effectively use this invaluable ... ... of a new tutorial suite for iHOP, or Information Hyperlinked Over Proteins. iHOP ...
Cached Medicine News:Health News:Ohio Dermatologists to Help Tennis Community Get Into the Swing of Sun Safety 2Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 2Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 3Health News:CHRISTUS Health Selects Five Elsevier Clinical Decision Support Solutions to Transform Care Delivery for Patients, Physicians, Nurses and Pharmacists 4Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 2Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 4Health News:The US Drug Watchdog Calls Zicam Nasal Gel Or Zicam Swabs A National Disaster That May Have Caused People To Lose Their Sense Of Smell 2Health News:Hispanics at High Risk for Colorectal Cancer 2Health News:Hispanics at High Risk for Colorectal Cancer 3Health News:New Online Tutorial for iHOP from OpenHelix 2Health News:New Online Tutorial for iHOP from OpenHelix 3
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces ... is available in its catalogue: ... Control (Sterilization, Disinfection, Testing and Treatment) ... Given the cost of ... has increased for solutions that can ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... U.S. IVD Industry http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... Care Act" (H.R. 3590) is complex legislation that ... many of its provisions are beginning to take ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 /PRNewswire/ ... research report is available in its catalogue: ... in France, Key Trends and Opportunities to ... Synopsis The report provides in ... the French personal accident and health insurance ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
... South Korea, Feb. 25 Dong-A PharmTech Co., ... Pharma, has initiated,a 200 patient, phase 2 proof ... udenafil, a long acting phosphodiesterase type 5 inhibitor, ... European,study is designed to investigate the safety and ...
... Enterprise Intelligence Systems to Healthcare Market, ... #1841 --,Harris Corporation (NYSE: HRS ), ... joined forces with Cancer Treatment,Services International (CTSI) ... oncology. Harris will provide advanced imaging and ...
Cached Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment 2
... When the all silicone cuff ... no distinguishable dimension to the ... shaft, yet it can be ... varied airway management needs. TTS™ ...
... Adjustable Neck Flange Hyperflex™ Tracheostomy TubesSimilar ... tube features the more traditional and ... Aire-Cuf® Adjustable Neck Flange Hyperflex™ Tracheostomy ... wedge, and obturator/introducer device., ,NOTE: ...
... for easy ventilator circuit attachment with or ... tubes are available in five adult sizes, ... system allows quick identification and correct sizing ... ,The Portex® line of D.I.C.® tracheostomy tubes ...
Indications For Usage: ,For use with percutaneous tracheotomies...
Medicine Products: